Kurobe Pharmaceuticals
Tampa, Florida, United States
About Kurobe Pharmaceuticals
Kurobe, headquartered in Tampa, has licensed a product from a Japanese company to treat methicillin-resistant staphylococcus aureus (MRSA) in the eye, said Barry Butler, president and CEO. Kurobe is one of several companies under the umbrella of Point Guard Partners LLC, established by former management executives at Sirion Holdings Inc. after that Tampa-based biopharma firm was sold in 2010. Butler, who was CEO of Sirion, is managing partner of Point Guard.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $5.0M
- Last round: Series Unknown (Jun 2013)
- Phone: +1 813-579-2550
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/kurobe-pharmaceuticals-2557723 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.